Table 1.
Sample characteristics of 9–13-year-olds in the U.S. who have and have not initiated HPV vaccination.
| Full sample |
Initiateda |
Not initiated |
||
|---|---|---|---|---|
| Measure | (n = 2185) | (n = 763) | (n = 1422) | p value |
| Age, n (%) | ||||
| 9 | 635 (29.1) | 163 (21.4)f | 472 (33.2)f | < .001 |
| 10 | 454 (20.8) | 136 (17.8)f | 318 (22.4)f | |
| 11 | 398 (18.2) | 121 (15.9)f | 277 (19.5)f | |
| 12 | 389 (17.8) | 194 (25.4)f | 195 (13.7)f | |
| 13 | 307 (14.1) | 149 (19.5)f | 158 (11.1)f | |
| Gender, n (%) | ||||
| Female | 1257 (57.5) | 464 (60.8) | 793 (55.8) | .02 |
| Male | 928 (42.5) | 299 (39.2) | 629 (44.2) | |
| Race/ethnicity, n (%)b | ||||
| Minority or multiracial/ethnic | 720 (33.8) | 303 (40.7) | 417 (30.0) | < .001 |
| White | 1413 (66.2) | 441 (59.3) | 972 (70.0) | |
| Geographic region, n (%)c | ||||
| Northeast | 391 (18.3) | 141 (18.9) | 250 (17.9) | .35 |
| Midwest | 500 (23.4) | 176 (23.6) | 324 (23.3) | |
| South | 814 (38.1) | 265 (35.5) | 549 (39.4) | |
| West | 433 (20.2) | 164 (22.0) | 269 (19.3) | |
| Puerto Rico | 1 (.0) | 0 (.0) | 1 (.1) | |
| Health insurance type, n (%) | ||||
| Private | 1298 (59.4) | 426 (55.8) | 872 (61.3) | .01 |
| Public/self-pay | 887 (40.6) | 337 (44.2) | 550 (38.7) | |
| Provider communication about HPV vaccine, n (%) | ||||
| Did not discuss | 989 (46.7) | 69 (9.0)f | 929 (69.5)f | < .001 |
| No recommendationd | 185 (8.7) | 65 (8.5) | 120 (8.4) | |
| Recommended | 504 (23.8) | 302 (39.6)f | 202 (14.2)f | |
| Strongly recommended | 438 (20.7) | 327 (42.9)f | 111 (7.8)f | |
| Sibling HPV vaccination status, n (%) | ||||
| Received | 627 (29.2) | 356 (47.5) | 271 (19.4) | < .001 |
| Did not receive/no older sibling | 1519 (70.8) | 393 (52.5) | 1125 (80.6) | |
| Flu vaccine in most recent flu season, n (%) | ||||
| Received | 1284 (59.1) | 573 (75.4) | 711 (50.4) | < .001 |
| Not received | 887 (40.9) | 187 (24.6) | 700 (49.6) | |
| Perceived benefits of vaccination, mean (SD) | 3.54 (.79) | 3.61 (.74) | 3.50 (.81) | .002 |
| Doctor, nurse, or other healthcare provider visit in past year, n (%) | ||||
| Yes | 2042 (93.6) | 731 (96.1) | 1311 (92.3) | .001 |
| No | 139 (6.4) | 30 (3.9) | 109 (7.7) | |
| Regular healthcare provider, n (%) | ||||
| Yes | 2087 (95.8) | 737 (96.7) | 1350 (95.3) | .11 |
| No | 92 (4.2) | 25 (3.3) | 67 (4.7) | |
| Service location, n (%) | ||||
| Private office | 1744 (79.8) | 540 (70.8) | 1204 (84.7) | < .001 |
| Other locatione | 441 (20.2) | 223 (29.2) | 218 (15.3) |
Note: Data were collected via a Web-based survey in 2014.
Among vaccine initiators, dose completion reported as follows: 1 dose, n = 283; 2 doses, n = 212; 3 doses, n = 268.
Child race/ethnicity was self-designated by participants as follows: African American/Black, 14.3%; American Indian, 2.3%; Asian, 4.7%; Hispanic or Latino, 13.0%; White, 75.2%; Native Hawaiian or other Pacific Islander, .9%; Other, 1.8%; No response, .3%. Mothers were asked to select multiple race/ethnicities when applicable. Participants were categorized as belonging to a racial/ethnic nonminority (i.e., White) or minority, (including 21.0% of participants who reported a single minority race/ethnicity and 12.8% who indicated multiple race/ethnicities).
Geographic location was determined from mother's reported zip code and categorized based on the U.S. census region.
Category includes mothers reporting that the vaccine was “neither recommended nor discouraged,” n = 174, “discouraged,” n = 9; or “strongly discouraged,” n = 2.
Includes community health clinic, university-based health clinic, emergency room or urgent care clinic, or other
For variables consisting of more than 2 categories, denotes significant group differences for that category at p < .05.